Could cause temporary or reversible harm; serious harm is unlikely.
Subpotent Drug- An out of specification ( OOS ) result observed in assay test during 18-month long term stability study.
| Brand name | CEFIXIME |
| Generic name | CEFIXIME |
| Active ingredient(s) | CEFIXIME |
| Distributed by / for | Lupin Pharmaceuticals, Inc., Baltimore, Maryland 21202 |
| NDC | 68180-405-01 |
| Full product label | Cefixime for Oral Suspension USP, 100 mg/5 mL, 50 mL bottle, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore, Maryland 21202, Manufactured by: Lupin Limited, Mandideep 462 046 INDIA, NDC 68180-405-01 |
| Recalling firm | Lupin Pharmaceuticals Inc. |
| Distribution | USA nationwide. |
| Quantity | 4554 bottles |
| Recall initiated | 2024-08-21 |
| Report date | 2024-09-04 |
| Recall completed | 2025-04-29 |
| Recall number | D-0648-2024 |
| Classification | Class II |
| FDA status | Terminated |
| Origin on file | Baltimore MD United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗